AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$NRIX

Why is Nurix Therapeutics stock collapsing 28% today?

Nurix Therapeutics (NRIX) stock fell 28.4% after Sanofi terminated a Phase 1 clinical trial for SAR448272, ending future milestone payments and royalties. Jefferies cut its price target from $45 to $36. Nurix has $1.1B in cash to fund operations until 2029, and other collaborations remain active.

Original reporting
investing.com
Published Nov 4, 2026, 9:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$NRIX
Bearish
high confidence
Mentioned
$NRIX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NRIXBearishHigh
01

Why it matters

The termination eliminates future payments, creating immediate earnings pressure and likely short‑term sell‑off.

02

Market read

A sharp, news‑driven price drop in a mid‑cap biotech highlights immediate trading opportunities.

03

What to watch

Sanofi may still support other NRIX assets, and the cash balance could fund new opportunities.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Nurix Therapeutics relies on collaborations for milestone payments; the Sanofi partnership was its largest program.

Company-level read

Ticker impact

$NRIXBearishHigh confidence
Context

Sanofi terminated the Phase 1 trial of SAR448272, causing NRIX to plunge 28% in pre‑market trading.

Expected impact

likely further downside as investors price in lost revenue potential

Evidence & confidence

The loss of a key partnered asset is a material catalyst and the stock already fell sharply.

Market effects

Sector

Biotech sector may see broader risk aversion toward partnered programs.

Regional

U.S. biotech stocks could face pressure in early trading.

Global

Limited to investors with exposure to NRIX and similar partnership models.

Counterpoint

What could challenge this read

The cash runway remains strong and other programs continue, suggesting a potential rebound if the market overreacts.

Key entities

  • Company
    Nurix Therapeutics

    Biotech firm developing oral STAT6 degrader.

  • Company
    Sanofi

    Pharmaceutical partner terminating the trial.

Read at source← All news

StorySanofi Ends Nurix’s STAT6 Drug Program, Removing Future Payments

Also covered by

3 outlets

Related articles

NOV 4
$SNYHighAI 8/10

Sanofi stops development of Nurix-partnered immune drug

Sanofi halted development of SAR448272, an immune disease drug licensed from Nurix, due to nonclinical findings. Nurix received a $10M payment earlier and shares dropped over 40%. Sanofi still sees potential in the STAT6 pathway but not this specific molecule. Nurix and Sanofi partnered in 2020 with a potential $2.5B deal.

finance.yahoo.com2 min
NOV 3
$NRIXHighAI 8/10

Nurix Shares Drop 35% After Sanofi Scraps Oral Immunology Drug — BigGo Finance

Nurix Therapeutics (NRIX) shares dropped 35% after Sanofi ended a Phase 1 study of an oral drug licensed from Nurix. The drug, SAR448272, was for inflammatory and autoimmune conditions. Nurix stands to lose $455M in potential milestones and royalties but retains other partnerships and $1.1B in cash. The company's other programs, including bexobrutinib in Phase 3, remain in development.

finance.biggo.com2 min
NOV 3
$NRIXMedAI 8/10

Sanofi Discontinues Nurix Therapeutics STAT6 Degrader Program

Sanofi ended a Phase 1 trial of STAT6 degrader SAR448272 and terminated the program, per a Nov. 3, 2026, notice to Nurix Therapeutics. Nurix remains eligible for milestone payments and royalties from other licensed programs under the Sanofi collaboration. Analysts have a Buy rating and $35.00 price target for NRIX, while Spark's AI Analyst rates it Neutral.

tipranks.com1 min